| Literature DB >> 12115487 |
Kazuhiro Suzuki1, Hidekazu Koike, Hiroshi Matsui, Yoshihiro Ono, Masaru Hasumi, Haruki Nakazato, Hironobu Okugi, Yoshitaka Sekine, Kazuya Oki, Kazuto Ito, Takumi Yamamoto, Yoshitatsu Fukabori, Kohei Kurokawa, Hidetoshi Yamanaka.
Abstract
Genistein is a major component of soybean isoflavone and has multiple functions resulting in antitumor effects. Prostate cancer is 1 of the targets for the preventive role of genistein. We examined the effect of genistein on human prostate cancer (LNCaP and PC-3) cells. Proliferation of both cell lines was inhibited by genistein treatment in a dose-dependent manner. To obtain the gene expression profile of genistein in LNCaP cells, we performed cDNA microarray analysis. The expression of many genes, including apoptosis inhibitor (survivin), DNA topoisomerase II, cell division cycle 6 (CDC6) and mitogen-activated protein kinase 6 (MAPK 6), was downregulated. Expression levels were increased more than 2-fold in only 4 genes. The glutathione peroxidase (GPx)-1 gene expression level was the most upregulated. Quantitative real-time polymerase chain reaction revealed significant elevation of transcript levels of GPx-1 in both LNCaP and PC-3 cells. Upregulation of gene expression levels accompanied elevation of GPx enzyme activities. In contrast, no significant changes were observed in the gene expression levels and enzyme activities of the other antioxidant enzymes, superoxide dismutase and catalase. GPx activation might be one of the important characteristics of the effects of genistein on prostate cancer cells. Copyright 2002 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12115487 DOI: 10.1002/ijc.10428
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396